Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
HLA-DQ β1 alleles associated with Epstein-Barr virus (EBV) infectivity and EBV gp42 binding to cells
Qingxue Li, Wei Bu, Erin Gabriel, Fiona Aguilar, Yo Hoshino, Hiroko Miyadera, Christoph Hess, Ronald L. Hornung, Amitava Roy, Jeffrey I. Cohen
Qingxue Li, Wei Bu, Erin Gabriel, Fiona Aguilar, Yo Hoshino, Hiroko Miyadera, Christoph Hess, Ronald L. Hornung, Amitava Roy, Jeffrey I. Cohen
View: Text | PDF
Research Article Virology

HLA-DQ β1 alleles associated with Epstein-Barr virus (EBV) infectivity and EBV gp42 binding to cells

  • Text
  • PDF
Abstract

Epstein-Barr virus (EBV) infects B cells and ~95% of adults are infected. EBV glycoprotein gp42 is essential for entry of virus into B cells. EBV gp42 binds to the β1 chain of HLA-DQ, -DR, and -DP on B cells, and uses these molecules for infection. To investigate if certain HLA-DQ alleles are associated with EBV seronegativity, we recruited ~3,300 healthy adult blood donors, identified 106 EBV-seronegative individuals, and randomly selected a control group of EBV-seropositive donors from the donor pool. A larger than expected proportion of EBV-seronegative subjects were HLA-DQ β1 *04/*05 and *06/*06, and to a lesser extent, *02/*03, compared with the control group, while a larger than expected portion of EBV-seropositive persons were HLA-DQ β1 *02/*02. We examined the ability of EBV gp42 to bind to different HLA-DQ molecules using human and mouse cells stably expressing these alleles. EBV gp42 bound less effectively to cells expressing HLA-DQ β1 *04/*05, *06/*06, or *03/*03 than to cells expressing HLA-DQ β1 *02/*02. These data are consistent with our observations of increased EBV seronegativity with DQ β1 *04/*05 or *06/*06 alleles. These findings emphasize the importance of a single genetic locus (HLA-DQ β1) to influence infectivity with EBV.

Authors

Qingxue Li, Wei Bu, Erin Gabriel, Fiona Aguilar, Yo Hoshino, Hiroko Miyadera, Christoph Hess, Ronald L. Hornung, Amitava Roy, Jeffrey I. Cohen

×

Figure 9

A neutralizing monoclonal antibody against gp42 blocks type 1 gp42 binding more efficiently than type 2 gp42 binding to human cells expressing different HLA class II alleles.

Options: View larger image (or click on image) Download as PowerPoint
A neutralizing monoclonal antibody against gp42 blocks type 1 gp42 bindi...
Type 1 (top) or type 2 (bottom) gp42 proteins were preincubated with monoclonal anti-gp42 Ab, F-2-1, or a control antibody at room temperature for 30 minutes, and added to human lymphoblastoid cell lines and binding was assayed as described in the legend to Figure 2 except that detection of His-tagged gp42 was performed using rabbit anti-His antibody (Cell Signaling Technology) followed by Alexa488-conjugated anti-rabbit secondary antibody. The relative percentage of gp42 binding to cells in the presence of F-2-1 antibody was calculated against that of the control antibody, which was set at 100%. The relative binding of gp42 in the presence of F-2-1 antibody is shown. MFI, mean fluorescence intensity. The data were derived from 6 independent experiments. Means (short horizontal lines) ± SEM (long horizontal lines) are shown.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts